HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport

Peihua LuoInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information

Zhifei XuInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information

Guanqun LiInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information

Hao YanInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information

Yi ZhuInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information

Hong ZhuInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information

Shenglin MaDepartment of Oncology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, ChinaView further author information

Bo YangInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information

Qiaojun HeInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information

Related Research Data